K. Jung

发表

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)

Steven J. M. Jones, S. Dunn, A. Cherkasov, 2013, Oncotarget.

Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays

K. Gopal, R. Lai, G. Bigras, 2014, Breast Cancer Research.

YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells

R. Lai, Peng Wang, Fang Wu, 2014, BMC Cancer.

High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer

J. Mackey, Sunita Ghosh, S. Damaraju, 2017, Oncotarget.

Granzyme B in Epithelial Barrier Dysfunction and Related Skin Diseases.

D. Granville, L. Nabai, K. Jung, 2022, American journal of physiology. Cell physiology.

Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays

K. Gopal, R. Lai, G. Bigras, 2014, Breast Cancer Research.

β-Catenin, a Sox2 binding partner, regulates the DNA binding and transcriptional activity of Sox2 in breast cancer cells.

Yupo Ma, K. Gopal, R. Lai, 2014, Cellular signalling.

Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity.

Yupo Ma, R. Lai, J. Pearson, 2012, Cellular signalling.

Granzyme B as a therapeutic target: an update in 2022

D. Granville, K. Jung, Michael Lane, 2022, Expert opinion on therapeutic targets.

Inhibitors of PARP: Number crunching and structure gazing

J. Rudolph, K. Luger, K. Jung, 2022, Proceedings of the National Academy of Sciences of the United States of America.

YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells

R. Lai, Peng Wang, Fang Wu, 2014, BMC Cancer.

Sox2 suppresses the invasiveness of breast cancer cells via a mechanism that is dependent on Twist1 and the status of Sox2 transcription activity

Peng Wang, Gilbert Bigras, Karen Jung, 2013, BMC Cancer.

Sox 2 suppresses the invasiveness of breast cancer c ells via a mechanism that is dependent on Twist 1 and the statu s of Sox 2 transcription activity

Yupo Ma, N. Kneteman, D. Douglas, 2013 .

Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter

N. Kneteman, K. Gopal, D. Douglas, 2015, Oncotarget.

Elevated ARG1 expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patients

R. Lai, Yaoxian Xu, J. Hanson, 2015, Cancer biology & therapy.

DDX17 (P72), a Sox2 binding partner, promotes stem-like features conferred by Sox2 in a small cell population in estrogen receptor-positive breast cancer.

K. Gopal, R. Lai, Liang Li, 2016, Cellular signalling.

DDX 17 ( P 72 ) , a Sox 2 binding partner , promotes stem-like features conferred by Sox 2 in a small cell population in estrogen receptor-positive breast cancer

K. Gopal, R. Lai, A. Alshareef, 2015 .

DDX17 (P72), a Sox2 binding partner, regulates Sox2 to sustain tumorigenic and stem-like properties in a phenotypically distinct subset of estrogen positive breast cancer cells By

A. Alshareef, L. Li, K. Jung, 2016 .